Current Studies 2017-05-10T19:48:42+00:00

Click on one of our study types below, or scroll to view our full list of available mental health studies.  If you find one of our psychopharmacology research studies that you’re interested in, fill out our easy volunteer form to apply.

Tardive DyskinesiaSchizophreniaMajor Depression

Disorder: Tardive Dyskinesia

Sponsor: Auspex

Study: SD-809-C-20 An Open-Label, Long-Term Safety Study Of Sd-809 (Dutetrabenazine) For The Treatment Of Moderate To Severe Tardive Dyskinesia

Description: This is an open-label trial of dutetrabenazine who have moderate to severe tardive dyskinesia.  It is open only for subjects who completed early trials of the same medication.

Demographics: Males and Females with moderate to severe TD ( this study is active but closed to new participants)

Ages: 18-65 years old

Study Coordinator: Melissa

Sponsor: Neurocrine Biosciences

Study: NBI-98854-1402 Phase 3, Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Tardive Dyskinesia

Description: This trial assesses the usefulness of a new medication NBI-98854 in treating tardive dyskinesia.  The study compares the responses of patients on the active medication with those on a placebo.

Demographics: Males and Females with moderate to severe TD

Ages: 18-59 years old (This study is active but no longer open to new participants)

Study Coordinator: Melissa

Sponsor: Neurocrine Biosciences

Study: NBI-98854-1506 Open-Label Rollover Study for Continuing Valbenazine (NBI-98854) Administration for the Treatment of Tardive Dyskinesia

Description: This study assesses the long term safety and effectiveness of NBI-98854.

Demographics: This study is only open for subjects who completed a prior study.

Study Coordinator: Melissa

Disorder: Schizophrenia

Sponsor: Janssen Research & Development

Study: FIRST RO92670SCH4043

Description:  This 6-month study looks at the importance of psychoeducation for both the patients with schizophrenia and their “caregivers.”  To participate in this study patients much have a caregiver who is also willing to participate.  All patients will be treated with medication, however only half of the caregivers will be given skills training and education.  The hope is that educating the caregiver benefits the patient.

Demographics: Males and Females

Ages: 18-60

Study Coordinator: Camille

Sponsor: Acadia

Study: ACP-103-034 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Adjunctive Pimavanserin for the Treatment of Schizophrenia.

Description:  This is a 6-week study for patients with schizophrenia.  It will enroll patients who are being treated but continue to experience symptoms.  Participants will continue on their current medication regime during this trial.  However, half of participants will have pimavanserin added to their medication regime, and the other half of participants will receive a placebo pill.

Demographics: Males and Females

Ages: 18 or older

Study Coordinator: Melissa & Cyndi

BIPI 1289.32 attenuated psychosis

Sponsor: Boehringer Ingelheim Pharmaceuticals, Inc.

Study: 1289.32 A Phase II Randomised, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy, Safety, And Tolerability Of Orally Administered BI 409306 During A 52-Week Treatment Period As An Early Intervention In Patients With Attenuated Psychosis Syndrome.

Description: This study tests whether BI 409306 prevents patients with a specific type of mental illness (attenuated psychosis syndrome) from becoming worse. This study looks at how well patients tolerate the medicine and how safe and effective it is over 1 year. Subject have an equal possibility of being assigned to placebo or active medication during this trial.

Demographics: Males and Females

Ages: 16 to 30 years old

Study Coordinators: Camille and Jerrah

Disorder: Major Depression

Sponsor: Janssen Research & Development

Study: OBSERVEMDD0001

Description:  The objective of this study is to search for self-reported or objective measures that can predict worsening of the depression.  This study will enroll subjects who are currently responding to treatment for major depression.  They will be evaluated every 8 weeks with a variety of materials and will also be asked to complete self-report measures in the weeks between visits.  Study subjects will continue taking their antidepressant medications throughout the study.

Demographics: Males and Females with depression who are responding successfully to a current treatment

Ages: 18-64

Study Coordinator: Camille

Sponsor: Janssen Research & Development

Study: NOPRODMDD0003 A Randomized, Multicenter, Crossover Study to Assess the Performance Validity and Test-Retest Reliability of a Computer-Administered Cognitive Test Battery in Subjects With Major Depressive Disorder

Description:  This study compares a computerized test of cognitive function with tests administered by doctors.  It is not designed to improve symptoms but to compare two forms of testing.  Testing will be done using both computers and investigators.   There will be 4 days of testing spread across 28 days.

Demographics:  Males and Females Patients are expected to be in partial or full remission.

Ages: 18-59

Study Coordinator: Camille

Sponsor: Alergen

Study: Rap-MD-03 A Randomized, Double-blind, Placebo-controlled, Multicenter Study of Rapastinel as Adjunctive Therapy in Major Depressive Disorder

Description:  This is a 3-week study for patients with depression.  It will enroll patients who are currently on an antidepressant but continue to experience depression.  Half of participants will receive rapastineal in addition to their current medications the rest will receive a placebo.  Participants who complete the trial will be eligible for other trials in which all subjects will receive rapastineal.

Demographics:  Males and Females Patients.

Ages: 18-65

Study Coordinator: Camille & Jerrah

Sponsor: Alergen

Study: RAP-MD-06 An Open-label, Long-term Safety Study of Rapastinel as Adjunctive Therapy in Patients with Major Depressive Disorder

Description:  This is a 52-week study which will assess the impact of adding rapastinel to current antidepressant medications.  It will enroll patients who are currently on an antidepressant but continue to experience depression.  All participants will receive active medication.  Participants in the RAP-MD-03 trial (see above) may be eligible for this trial too.

Demographics: Males and Females

Ages: 18-65

Study Coordinator: Camille & Jerrah

Resources

ClinicalTrials.gov provides easy and free access to information on clinical studies around the world.  The trials we participate in are registered with this website.  This website also includes a glossary of terms related to clinical studies, clinical trials and medical research.